Article Text

PDF
Rituximab treatment for peripheral ulcerative keratitis associated with Wegener’s granulomatosis
  1. Julie Freidlin,
  2. Ira G Wong,
  3. Nisha Acharya
  1. F I Proctor Foundation, 95 Kirkham Street, University of California, San Francisco, CAlifornia, USA
  1. Nisha Achanrya, F I Proctor Foundation, 95 Kirkham Street, University of California, San Francisco, CA 94143, USA; Nisha.Acharya{at}yahoo.com

Statistics from Altmetric.com

Rituximab is a chimeric antibody against CD20 aimed at depleting B cells. While originally developed as a treatment for B cell lymphomas, it was recently found to be useful in managing autoimmune diseases including refractory Wegener’s granulomatosis.13 We report a case of refractory peripheral ulcerative keratitis (PUK) associated with Wegener’s granulomatosis that was successfully treated with rituximab.

Case report

A 57 year old man with longstanding Wegener’s granulomatosis was admitted to the hospital with severe pain and blurred vision in the left eye as well as respiratory compromise because of tracheal …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.